P.A.W. Capital’s Cue Biopharma CUE Stock Holding History

P.A.W. Capital’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,000	Closed	-$536K	–	20
2023 Q1	$536K	Sell	5,000 -1,000	-17%	-$95.4K	1.18%	21
2022 Q4	$513K	Sell	6,000 -667	-10%	-$61K	1.4%	21
2022 Q3	$446K	Buy	6,667 +834	+14%	+$71.7K	0.67%	48
2022 Q2	$436K	Buy	5,833 +833	+17%	+$97.4K	0.63%	51
2022 Q1	$732K	Buy	5,000 +1,000	+25%	+$212K	0.77%	54
2021 Q4	$1.36M	Sell	4,000 -167	-4%	-$64.6K	1.24%	20
2021 Q3	$1.82M	Hold	4,167	–	–	1.62%	18
2021 Q2	$1.46M	Sell	4,167 -500	-11%	-$194K	1.22%	29
2021 Q1	$1.71M	Hold	4,667	–	–	1.5%	21
2020 Q4	$1.75M	Buy	+4,667	New	+$1.86M	1.54%	21
2018 Q4	–	Sell	-2,667	Closed	-$724K	–	65
2018 Q3	$724K	Buy	2,667 +1,667	+167%	+$482K	0.77%	37
2018 Q2	$356K	Hold	1,000	–	–	0.36%	62
2018 Q1	$422K	Buy	+1,000	New	+$456K	0.51%	57

Other funds holding CUE

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

P.A.W. Capital's CUE Position: Q2 2023 in Review

P.A.W. Capital sold out of Cue Biopharma (CUE) in Q2 2023, closing a stake of 5,000 shares — an estimated $536K sold.

P.A.W. Capital first reported a position in CUE in Q1 2018 and held it in 13 quarters. The position peaked at $1.82M in Q3 2021. 78 funds tracked by Wall St. Rank hold CUE as of Q2 2023.

P.A.W. Capital reported no remaining Cue Biopharma position as of Q2 2023 after selling out during the quarter.
P.A.W. Capital sold 5,000 Cue Biopharma shares in Q2 2023, an estimated $536K.
P.A.W. Capital first reported a position in Cue Biopharma in Q1 2018 and held it in 13 quarters.
P.A.W. Capital's Cue Biopharma position peaked at $1.82M in Q3 2021.
78 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2023.

Based on P.A.W. Capital's 13F filing for Q2 2023, filed 24 Jul 2023.